SK872003A3 - Preparation with vascular protective and anti-oxidative effect and use thereof - Google Patents

Preparation with vascular protective and anti-oxidative effect and use thereof Download PDF

Info

Publication number: SK872003A3
Authority: SK; Slovakia
Prior art keywords: ldl; terpinene; oxidation; composition according; composition
Prior art date: 2000-07-28

Application number

SK87-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Erich Elstner

Original Assignee

Steigerwald Arzneimittelwerk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-28

Filing date

2001-05-28

Publication date

2003-06-03

2001-05-28 Application filed by Steigerwald Arzneimittelwerk filed Critical Steigerwald Arzneimittelwerk

2003-06-03 Publication of SK872003A3 publication Critical patent/SK872003A3/sk

Links

230000002792 vascular Effects 0.000 title claims abstract description 7
230000001681 protective effect Effects 0.000 title claims abstract description 5
230000003078 antioxidant effect Effects 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title abstract description 6
229930006978 terpinene Natural products 0.000 claims abstract description 11
150000003507 terpinene derivatives Chemical class 0.000 claims abstract description 11
239000000341 volatile oil Substances 0.000 claims abstract description 8
YKFLAYDHMOASIY-UHFFFAOYSA-N terpinene-gamma Natural products CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 claims description 35
239000000203 mixture Substances 0.000 claims description 20
235000019501 Lemon oil Nutrition 0.000 claims description 10
239000010501 lemon oil Substances 0.000 claims description 10
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 7
239000000047 product Substances 0.000 claims description 6
235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 4
235000015872 dietary supplement Nutrition 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
235000005911 diet Nutrition 0.000 claims description 3
230000000378 dietary effect Effects 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
125000000293 gamma-terpinene group Chemical group 0.000 claims 1
201000001320 Atherosclerosis Diseases 0.000 abstract description 9
108010007622 LDL Lipoproteins Proteins 0.000 description 43
102000007330 LDL Lipoproteins Human genes 0.000 description 43
230000003647 oxidation Effects 0.000 description 16
238000007254 oxidation reaction Methods 0.000 description 16
239000010949 copper Substances 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
150000001993 dienes Chemical class 0.000 description 8
230000000694 effects Effects 0.000 description 8
210000002381 plasma Anatomy 0.000 description 8
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
238000009825 accumulation Methods 0.000 description 7
235000013312 flour Nutrition 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
238000011161 development Methods 0.000 description 5
108010010234 HDL Lipoproteins Proteins 0.000 description 4
102000015779 HDL Lipoproteins Human genes 0.000 description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
229940087168 alpha tocopherol Drugs 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
239000003086 colorant Substances 0.000 description 4
239000003925 fat Substances 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
229960000984 tocofersolan Drugs 0.000 description 4
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
239000002076 α-tocopherol Substances 0.000 description 4
235000004835 α-tocopherol Nutrition 0.000 description 4
108010008150 Apolipoprotein B-100 Proteins 0.000 description 3
102000006991 Apolipoprotein B-100 Human genes 0.000 description 3
238000008214 LDL Cholesterol Methods 0.000 description 3
102000004895 Lipoproteins Human genes 0.000 description 3
108090001030 Lipoproteins Proteins 0.000 description 3
108010062497 VLDL Lipoproteins Proteins 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
238000000034 method Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
-1 peroxyl fatty acid radicals Chemical class 0.000 description 3
230000006318 protein oxidation Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
238000012360 testing method Methods 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
235000013912 Ceratonia siliqua Nutrition 0.000 description 2
240000008886 Ceratonia siliqua Species 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000004075 alteration Effects 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003859 lipid peroxidation Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229940097156 peroxyl Drugs 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
235000002639 sodium chloride Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
210000004026 tunica intima Anatomy 0.000 description 2
CTMLKIKAUFEMLE-FTNGGYTGSA-N (2s)-4-[(e)-2-[(2s)-2-carboxy-6-hydroxy-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydroindol-1-yl]ethenyl]-2,3-dihydropyridine-2,6-dicarboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1N(\C=C\C=1C[C@H](N=C(C=1)C(O)=O)C(O)=O)[C@H](C(O)=O)C2 CTMLKIKAUFEMLE-FTNGGYTGSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
240000008620 Fagopyrum esculentum Species 0.000 description 1
235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000019463 artificial additive Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000005473 carotenes Nutrition 0.000 description 1
150000001746 carotenes Chemical class 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000009843 endothelial lesion Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
235000019462 natural additive Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Natural Medicines & Medicinal Plants (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Vascular Medicine (AREA)
Medical Informatics (AREA)
Botany (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)

SK87-2003A 2000-07-28 2001-05-28 Preparation with vascular protective and anti-oxidative effect and use thereof SK872003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10038640A DE10038640A1 (de)	2000-07-28	2000-07-28	Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung
PCT/DE2001/002082 WO2002009685A1 (de)	2000-07-28	2001-05-28	Präparat mit gefässschützender und antioxidativer wirkung sowie dessen verwendung

Publications (1)

Publication Number	Publication Date
SK872003A3 true SK872003A3 (en)	2003-06-03

Family

ID=7651698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK87-2003A SK872003A3 (en)	2000-07-28	2001-05-28	Preparation with vascular protective and anti-oxidative effect and use thereof

Country Status (18)

Country	Link
US (1)	US20040047922A1 (cs)
EP (1)	EP1305013A1 (cs)
JP (1)	JP2004513077A (cs)
CN (1)	CN1444475A (cs)
AU (1)	AU2001267324A1 (cs)
BR (1)	BR0112663A (cs)
CA (1)	CA2411907A1 (cs)
CZ (1)	CZ2003194A3 (cs)
DE (2)	DE10038640A1 (cs)
EE (1)	EE200300044A (cs)
MX (1)	MXPA03000718A (cs)
NO (1)	NO20030412L (cs)
NZ (1)	NZ523185A (cs)
PL (1)	PL364992A1 (cs)
RU (1)	RU2003105695A (cs)
SK (1)	SK872003A3 (cs)
WO (1)	WO2002009685A1 (cs)
ZA (1)	ZA200210123B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6616942B1 (en)	1999-03-29	2003-09-09	Soft Gel Technologies, Inc.	Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US7588786B2 (en)	2001-11-14	2009-09-15	Jarrow Formulas, Inc.	Eutectic-based self-nanoemulsified drug delivery system
KR20060082791A (ko) *	2003-06-25	2006-07-19	찰스 에르윈	코엔자임 ｑ10의 전달을 증가시키기 위한 화학적 배합물 및방법
US20080089877A1 (en) *	2003-08-14	2008-04-17	Udell Ronald G	Super Absorption Coenzyme Q10
US8105583B2 (en) *	2003-09-29	2012-01-31	Soft Gel Technologies, Inc.	Solubilized CoQ-10
US8124072B2 (en)	2003-09-29	2012-02-28	Soft Gel Technologies, Inc.	Solubilized CoQ-10
US7169385B2 (en) *	2003-09-29	2007-01-30	Ronald G. Udell	Solubilized CoQ-10 and carnitine
US8343541B2 (en)	2007-03-15	2013-01-01	Soft Gel Technologies, Inc.	Ubiquinol and alpha lipoic acid compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1343561A (en) *	1972-03-23	1974-01-10	Hisamitsu Pharmaceutical Co	Substances for use in the treatment of gallstones
US4246287A (en) *	1979-10-26	1981-01-20	International Flavors & Fragrances Inc.	Flavoring with fenchyl ethyl ether
JPS60172925A (ja) *	1984-02-17	1985-09-06	Kao Corp	胆石溶解剤
JPS60204722A (ja) *	1984-03-28	1985-10-16	Junichi Iwamura	高脂血症改善・予防剤
CA2073353C (fr) *	1990-11-14	2003-10-28	Alexandre Zysman	Composes amphiphiles non-ioniques derives du glycerol, leur procede de preparation, composes intermediaires correspondants et compositions contenant lesdits composes
AU659625B2 (en) *	1991-01-18	1995-05-25	Clilco, Ltd.	Lice-repellant compositions
JPH08275728A (ja) *	1995-04-06	1996-10-22	New Aqua Gijutsu Kenkyusho:Kk	Ｄｈａ油を主成分とする食用油
US5891465A (en) *	1996-05-14	1999-04-06	Biozone Laboratories, Inc.	Delivery of biologically active material in a liposomal formulation for administration into the mouth
EP1021177A4 (en) *	1997-02-04	2002-05-15	John V Kosbab	COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
US5925335A (en) *	1997-06-12	1999-07-20	C.S. Bioscience Inc.	Dental formulation
DE19915102A1 (de) *	1999-04-01	2000-10-05	Pohl Boskamp Gmbh Chem Pharma	Verwendung von Limonen zur Behandlung oxidativer Zellschädigungen
US20020048551A1 (en) *	1999-04-06	2002-04-25	Keller Brian C.	Delivery of biologically active material in a liposomal formulation for administration into the mouth

2000
- 2000-07-28 DE DE10038640A patent/DE10038640A1/de not_active Withdrawn
2001
- 2001-05-28 EE EEP200300044A patent/EE200300044A/xx unknown
- 2001-05-28 CN CN01813403A patent/CN1444475A/zh active Pending
- 2001-05-28 DE DE10192998T patent/DE10192998D2/de not_active Expired - Fee Related
- 2001-05-28 CZ CZ2003194A patent/CZ2003194A3/cs unknown
- 2001-05-28 US US10/311,730 patent/US20040047922A1/en not_active Abandoned
- 2001-05-28 PL PL01364992A patent/PL364992A1/xx not_active Application Discontinuation
- 2001-05-28 MX MXPA03000718A patent/MXPA03000718A/es not_active Application Discontinuation
- 2001-05-28 SK SK87-2003A patent/SK872003A3/sk not_active Application Discontinuation
- 2001-05-28 RU RU2003105695/15A patent/RU2003105695A/ru not_active Application Discontinuation
- 2001-05-28 NZ NZ523185A patent/NZ523185A/en unknown
- 2001-05-28 WO PCT/DE2001/002082 patent/WO2002009685A1/de not_active Ceased
- 2001-05-28 EP EP01944968A patent/EP1305013A1/de not_active Withdrawn
- 2001-05-28 AU AU2001267324A patent/AU2001267324A1/en not_active Abandoned
- 2001-05-28 CA CA002411907A patent/CA2411907A1/en not_active Abandoned
- 2001-05-28 BR BR0112663-6A patent/BR0112663A/pt not_active Application Discontinuation
- 2001-05-28 JP JP2002515238A patent/JP2004513077A/ja active Pending
2002
- 2002-12-13 ZA ZA200210123A patent/ZA200210123B/xx unknown
2003
- 2003-01-27 NO NO20030412A patent/NO20030412L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA03000718A (es)	2003-06-04
NO20030412L (no)	2003-02-11
ZA200210123B (en)	2003-05-27
BR0112663A (pt)	2003-06-24
NO20030412D0 (no)	2003-01-27
AU2001267324A1 (en)	2002-02-13
CA2411907A1 (en)	2002-12-05
DE10038640A1 (de)	2002-02-14
WO2002009685A1 (de)	2002-02-07
US20040047922A1 (en)	2004-03-11
JP2004513077A (ja)	2004-04-30
CN1444475A (zh)	2003-09-24
NZ523185A (en)	2005-07-29
EP1305013A1 (de)	2003-05-02
CZ2003194A3 (cs)	2003-05-14
RU2003105695A (ru)	2004-06-27
EE200300044A (et)	2004-10-15
PL364992A1 (en)	2004-12-27
DE10192998D2 (de)	2003-01-16

Legal Events

Date	Code	Title	Description
2010-08-09	FC9A	Refused patent application

Publication	Publication Date	Title
US4603142A (en)	1986-07-29	Cholesterol lowering method of use
US6204290B1 (en)	2001-03-20	Tocotrienols and tocotrienol-like compounds and methods for their use
US20010046548A1 (en)	2001-11-29	Anticholesterolemic edible oil
JP2015514131A (ja)	2015-05-18	代謝症候群および高コレステロール血症に関連する心血管代謝リスク因子を低減および制御するための、栄養化合物ジヒドロケルセチン（タキシフォリン）およびジヒドロケルセチン（タキシフォリン）と組み合わせたアラビノガラクタンの使用方法
Abeywardena et al.	2002	Polyphenol‐enriched extract of oil palm fronds (Elaeis guineensis) promotes vascular relaxation via endothelium‐dependent mechanisms
Ramadan et al.	2013	Goldenberry (P hysalis peruviana) Juice Rich in Health‐Beneficial Compounds Suppresses High‐Cholesterol Diet‐Induced Hypercholesterolemia in Rats
AU2004210244B9 (en)	2009-02-05	Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides
Srivastava	1986	Vitamin E exerts antiaggregatory effects without inhibiting the enzymes of the arachidonic acid cascade in platelets
CA2440065A1 (en)	2002-09-12	Dietary supplement compositions
Trovato et al.	1996	Effects of fruit juices of Citrus sinensis L. and Citrus limon L. on experimental hypercholesterolemia in the rat
EP1848451A2 (en)	2007-10-31	Therapeutic uses of tomato extracts
SK872003A3 (en)	2003-06-03	Preparation with vascular protective and anti-oxidative effect and use thereof
US20120156185A1 (en)	2012-06-21	Nutritional compositions comprising citrus fibers
JP2013528163A (ja)	2013-07-08	心臓血管疾患を治療するためのリンゴ果皮抽出物
KR20030085123A (ko)	2003-11-03	항콜레스테롤 식용 기름
US5972357A (en)	1999-10-26	Healthy foods and cosmetics
US20020192318A1 (en)	2002-12-19	Anticholesterolemic edible oil
CA2350220C (en)	2008-06-17	Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
HK1057008A (en)	2004-03-12	Preparation with vascular protective and anti-oxidative effect and use thereof
KR100690980B1 (ko)	2007-03-12	콜레스테롤 분해용 음료 및 분해용 제재
KR100291143B1 (ko)	2001-05-15	나린진 또는 나린제닌을 포함하는 아실 코에이:콜레스테롤-오-아실트랜스퍼레이즈 저해제 조성물
KR20000023557A (ko)	2000-04-25	헤스페리딘 또는 헤스페레틴을 포함하는 아실 코에이:콜레스테롤-오-아실트랜스퍼레이즈 저해제 조성물
Ghulam Rasool	2005	Effect Of Commercially Available Vitamin E Preparations On Arterial Compliance And Selected Cardiovascular Parameters [QP772. T6 A288 2006 f rb].
KR19990079062A (ko)	1999-11-05	나린진 또는 나린제닌을 포함하는 동맥경화증 예방 및 치료용조성물
JP2008513350A (ja)	2008-05-01	フラボノイドとトコトリエノールを含む組成物及びその方法